MRX 6 / Akari Therap - LARVOL DELTA

C012013: Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2% (clinicaltrials.gov) - P2; N=73; Terminated; Sponsor: Celsus Therapeutics PLC; Recruiting ➔ Terminated; Trial primary completion date: Dec 2014 ➔ Mar 2015

Trial primary completion date • Trial termination • Biosimilar • Dermatitis • Eczema • Immunology

Mrx6 regulates mitochondrial DNA copy number in S. cerevisiae by engaging the evolutionarily conserved Lon protease Pim1. (PubMed, Mol Biol Cell) - "No further increase of mtDNA copy number was observed upon depletion of Pim1 in Δmrx6 cells, revealing an epistatic relationship between Pim1 and Mrx6. Human and bacterial Lon proteases regulate DNA replication by degrading replication initiation factors, suggesting a model in which Pim1 acts similarly with the Mrx6 complex providing a scaffold linking it to mtDNA."

Journal